Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of... The post SOHO 202...

Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lympho...

The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib... The post...

Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for... The post IMW 2021: treatment-...

The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel... The post Highl...

Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence... ...

Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;... The post CAR-T...

Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20....

A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older... The post EH...

Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in... The ...